RxAll is a health-tech company founded in 2016 that builds digital infrastructure for pharmacies, including AI-powered drug testing scanners, pharmacy management software, and invoice financing tools[1][2][3]. It serves pharmacies, hospitals, wholesalers, and drug regulators primarily in Africa—powering over 5,000 pharmacies across Nigeria, Kenya, and Uganda to deliver quality healthcare to more than 2.5 million patients monthly—by combating counterfeit drugs, enabling post-marketing surveillance, and streamlining operations like inventory management and e-commerce[2][3][4]. The company has raised $3.33M, achieved profitability, and protected millions of lives by testing over 300 drug types[1][3][4][5].
RxAll was founded in 2016 by Adebayo Alonge, a BCG alum with expertise in data analysis, who prototyped the first RxScanner—an AI-powered handheld device combining spectrometry—in his New Haven, Connecticut garage to tackle Africa's rampant counterfeit drug problem[3][4][5]. The idea emerged from Alonge's recognition that poor-quality medicines undermine healthcare access, prompting development of hardware and software for instant quality checks in 20 seconds via a connected app and cloud AI[3]. Early traction came from securing over 100 pharmacy customers; the COVID-19 pandemic accelerated growth in 2020 when RxAll rapidly launched an e-commerce platform for online sales and deliveries, leading to viral adoption via pharmacist recommendations, scaling to thousands of users despite funding hurdles—ultimately closing $3.15M in 2021 and reaching profitability[4].
RxAll rides the wave of AI-driven health-tech in emerging markets, addressing Africa's counterfeit drug crisis (affecting up to 30% of medicines) amid rising demand for accessible, verifiable healthcare post-COVID[3][4]. Its timing aligns with smartphone penetration, cloud AI scalability, and e-pharmacy booms, amplified by market forces like regulatory pushes for post-marketing surveillance and independent pharmacies' need to digitize amid fragmentation[1][3]. By empowering local pharmacies as quality gatekeepers, RxAll influences the ecosystem—differentiating providers, reducing waste/shortages, informing FDA interventions, and fostering data ecosystems that could expand pan-African standards for safe meds[2][3].
RxAll's profitability and scanner iterations position it for pan-African (and global) expansion, potentially integrating advanced AI for predictive analytics or blockchain traceability amid trends like telehealth and regulatory tech[3][5]. Rising investor interest in African health-tech, coupled with data flywheels from millions of tests, could amplify its role as a quality assurance standard-setter. As counterfeit threats persist, RxAll's mission to make quality healthcare ubiquitous ties back to its garage origins—poised to protect even more lives through trusted digital infrastructure.
RxAll has raised $2.0M in total across 1 funding round.
RxAll's investors include L'ATTITUDE Ventures, LvlUp Ventures, Osney Capital, Quake Capital, SOSV.
RxAll has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $2.0M Seed | L'ATTITUDE Ventures, LvlUp Ventures, Osney Capital, Quake Capital, SOSV |
